Is Tarlatamab a targeted therapy drug?

Tarlatamab (Tarlatamab) is a new bispecific T cell-adaptive antibody (BiTE), which mainly binds simultaneously TCD3molecules on the surface of Tcells and DLL3 on the surface of tumor cells (Delta-like ligand 3) antigen to achieve targeted killing of tumor cells by TT cells. Although it is not a small molecule targeted drug in the traditional sense, its mechanism of accurately recognizing specific tumor antigens has "targeting" characteristics in nature, so it can be classified as a new type of targeted immunotherapy drug.

Talatumumab's targetDLL3 is an antigen mainly expressed in neuroendocrine tumors such as small cell lung cancer (SCLC). Its expression is extremely low in normal tissues, so it is highly tumor specific. This characteristic gives it a significant targeting advantage in the treatment of DLL3 positive tumors such as small cell lung cancer. It also reduces the risk of damage to normal cells and enhances the safety and precision of treatment.

Different from traditional tyrosine kinase inhibitor (TKI) targeted drugs, talatumumab directly recruits the patient's own T cells for immune attack through a bispecific antibody structure, which is a new treatment model of targeted immune combination. This mechanism is not only targeted, but also integrates the durability and potential memory response of immunotherapy. It has been an important research direction in the field of tumor treatment in recent years.

Talatumumab is currently being used in clinical studies for the treatment of relapsed or refractory small cell lung cancer, and preliminary data shows good efficacy and safety. In the future, its indications are expected to be expanded to more DLL3-expressing tumors. When receiving such treatment, patients should receive medication management in professional medical institutions and be closely monitored for possible immune-related side effects such as cytokine release syndrome (CRS) to ensure the effectiveness and safety of the treatment.

Reference materials:https://www.drugs.com/

xa0